{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Repare Therapeutics Inc."},"Symbol":{"label":"Symbol","value":"RPTX"},"Address":{"label":"Address","value":"7210 FREDERICK-BANTING STREET,SUITE 100, SAINT-LAURENT, Quebec, H4S 2A1, Canada"},"Phone":{"label":"Phone","value":"+1 857 412-7018"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Repare Therapeutics Inc is a precision oncology company engaged in the discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations."},"CompanyUrl":{"label":"Company Url","value":"https://www.reparerx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Lloyd M. Segal","title":"President, CEO, Secretary & Director"},{"name":"Maria Koehler","title":"Chief Medical Officer & Executive Vice President"},{"name":"Michael Zinda","title":"Chief Scientific Officer & Executive VP"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}